ICON Public (NASDAQ:ICLR) Sets New 1-Year Low - Time to Sell?

ICON Public Limited (NASDAQ:ICLR - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $133.28 and last traded at $136.79, with a volume of 3967892 shares traded. The stock had previously closed at $137.23.

Wall Street Analysts Forecast Growth

ICLR has been the topic of several recent research reports. Robert W. Baird reduced their target price on shares of ICON Public from $221.00 to $203.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Truist Financial dropped their target price on ICON Public from $262.00 to $208.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. Citigroup lowered their price objective on shares of ICON Public from $290.00 to $215.00 and set a "buy" rating for the company in a research report on Monday, April 7th. TD Cowen cut shares of ICON Public from a "buy" rating to a "hold" rating and reduced their target price for the stock from $254.00 to $157.00 in a research report on Monday, April 14th. Finally, Barclays reaffirmed an "equal weight" rating and set a $165.00 price target (down previously from $240.00) on shares of ICON Public in a research note on Thursday, April 10th. Seven analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $232.67.

ICON Public Stock Down 0.7 %

The stock's fifty day simple moving average is $170.17 and its two-hundred day simple moving average is $201.25. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34. The company has a market capitalization of $11.71 billion, a price-to-earnings ratio of 15.21, a PEG ratio of 1.86 and a beta of 1.24.

ICON Public (NASDAQ:ICLR - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, beating analysts' consensus estimates of $3.41 by $0.01. The company had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. On average, sell-side analysts predict that ICON Public Limited will post 13.38 earnings per share for the current fiscal year.

Institutional Trading of ICON Public

Hedge funds have recently bought and sold shares of the company. Sierra Ocean LLC bought a new stake in shares of ICON Public during the fourth quarter valued at approximately $29,000. Park Place Capital Corp boosted its position in ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company's stock worth $47,000 after acquiring an additional 166 shares during the period. Private Trust Co. NA boosted its position in ICON Public by 48.8% during the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company's stock worth $52,000 after acquiring an additional 82 shares during the period. NBC Securities Inc. acquired a new position in shares of ICON Public during the first quarter valued at $59,000. Finally, GAMMA Investing LLC raised its stake in shares of ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company's stock valued at $91,000 after purchasing an additional 169 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.